It was a pleasure to discuss with Prof. Denis Poddubnyy (Charité-Universitätsmedizin Berlin, Berlin, Germany) the post-hoc analysis from sub-populations of the phase 3 SPIRIT-1 (NCT01695239) and SPIRIT-2 (NCT02349295) trials aimed at determining the efficacy of ixekizumab in reducing axial symptoms and improving quality of life in patients with PsA and symptoms of axial involvement.
The abstract entitled ‘Ixekizumab Efficacy in Patients with Psoriatic Arthritis Presenting with Symptoms Indicative of Axial Involvement’ (ABSTRACT NUMBER: 1347) was presented at the ACR Convergence, 5-9 November.
- What are the manifestations of axial involvement in psoriatic arthritis and what are their prevalence? (0:13)
- Could you tell us a little about the efficacy of ixekizumab in psoriatic arthritis and the post-hoc analysis you conducted? (1:02)
- What were the findings of the analysis? (2:09)
Disclosures: Prof Poddubnyy has received research support from AbbVie, Eli Lilly, MSD, Novartis, and Pfizer; consulting fees from AbbVie, Biocad, Eli Lilly, Gilead, GlaxoSmithKline, Janssen, MSD, Novartis, Pfizer, Samsung Bioepis, and UCB; and speaker fees from AbbVie, Bristol-Myers Squibb, Eli Lilly, MSD, Novartis, Pfizer, and UCB.
Support: Interview and filming supported by Touch Medical Media Ltd. Interview conducted by Gina Furnival.
Filmed in coverage of virtual ACR Convergence 2021.
Share this Video
Related Videos In Psoriatic Arthritis
Merav Lidar, ACR 2021: Efficacy and Safety of Risankizumab in Psoriatic Arthritis
Prof. Merav Lidar (Sheba Medical Center, Tel Hashomer, Israel) kindly took the time to discuss the 24-week efficacy and safety results from the KEEPsaKE2 trial (NCT03671148). This phase 3 randomized, double-blind trial investigated the humanized immunoglobulin G1 monoclonal antibody, risankizumab, in adults with psoriatic arthritis (PsA). The abstract entitled ‘Efficacy and Safety of Risankizumab for […]
Ana-Maria Orbai, ACR 2021: Effect of Guselkumab on General Health Outcomes using the PROMIS-29
touchIMMUNOLOGY had the pleasure of discussing with Dr Ana-Maria Orbai (Johns Hopkins University School of Medicine, Baltimore, MD, USA) the Patient-Reported Outcomes Measurement Information System-29 (PROMIS-29) instrument and its use in assessing the effect of guselkumab on general health outcomes in patients with psoriatic arthritis in the DISCOVER-1 trial (NCT03162796). The abstract entitled ‘Guselkumab-Treated Patients […]
Laure Gossec, ACR 2021: Long-term Impact of Bimekizumab on Patient-reported Outcomes in PsA
Prof. Laure Gossec (Sorbonne Universite, Paris, France) kindly took the time to speak with touchIMMUNOLOGY about the long-term impact of the IgG1 inhibitor, bimekizumab, on patient-reported outcomes from the phase 2b BE ACTIVE study (NCT02969525) and its open-label extension, the OLE trial (NCT03347110). The poster entitled ‘Sustained Improvement in Physical Function, Disease Impact and Health-Related […]
Journal articles and more to your inbox
Get the latest clinical insights from touchIMMUNOLOGYSign me up!